本文選題：非肌層浸潤性膀胱癌　切入點(diǎn)：二次電切　出處：《實(shí)用醫(yī)學(xué)雜志》2015年03期 　論文類型：期刊論文

【摘要】：目的:探討二次電切(repeat transurethral resection,re-TUR)治療高危非肌層浸潤性膀胱癌(non-muscle invasive bladder cancer,NMIBC)的臨床意義。方法 :收集68例首次經(jīng)尿道電切術(shù)(transurethral resection,TUR)診斷為高危NMIBC的患者資料,其中28例2~6周內(nèi)接受re-TUR(觀察組),40例未接受re-TUR(對照組),術(shù)后常規(guī)吡柔比星膀胱灌注化療。評估首次TUR腫瘤殘留率及病理分期的低估率,并比較兩組膀胱腫瘤復(fù)發(fā)、進(jìn)展情況。結(jié)果:觀察組腫瘤殘留率為46.43%(13/28),病理分期低估率為21.43%(6/28)。隨訪12~48個月(平均25個月),觀察組腫瘤殘留者與無腫瘤殘留者的進(jìn)展率分別為44.44%、6.67%(P0.05);觀察組腫瘤總復(fù)發(fā)率及1、2年內(nèi)復(fù)發(fā)率均比對照組低(P0.05),但在進(jìn)展方面兩組無差異(P0.05)。結(jié)論:高危NMIBC電切術(shù)后腫瘤殘留率、復(fù)發(fā)率、進(jìn)展率高。re-TUR治療高危NMIBC不僅在診斷和治療,而且在預(yù)后判斷方面都具有臨床應(yīng)用價(jià)值,但re-TUR不能夠延緩膀胱腫瘤進(jìn)展,仍需輔助其他方法進(jìn)行綜合治療。
[Abstract]:Objective: To investigate the two TURP (repeat transurethral resection, re-TUR) for high-risk non muscle invasive bladder cancer (non-muscle invasive bladder cancer, NMIBC) and the clinical significance. Methods: We collected 68 cases of the first transurethral resection (transurethral resection, TUR) diagnosis for patients with high-risk NMIBC data, including 28 cases of 2~6 take re-TUR weeks (observation group), 40 patients received re-TUR (control group), after routine intravesical instillation of pirarubicin chemotherapy. Assessing the TUR tumor residual rate and pathological staging underestimated the rate, and compare the two groups of bladder tumor recurrence and progress. Results: in the observation group, the residual tumor rate was 46.43% (13/28), pathological staging underestimated the rate of 21.43% (6/28). The follow-up of 12~48 months (average 25 months) in the observation group, tumor residual and no tumor residual rate were 44.44%, 6.67% (P0.05); the observation group total tumor recurrence rate and recurrence rate were 1,2 years Lower than the control group (P0.05), but in the progress of no significant difference between two groups (P0.05). Conclusion: high risk NMIBC residual tumor after transurethral resection rate, recurrence rate, high rate of progress of.Re-TUR for high risk NMIBC not only in the diagnosis and treatment, and the judgment has clinical value in prognosis, but re-TUR can not delay bladder tumor progression, still need to assist other methods of treatment.

【作者單位】： 廣西自治區(qū)人民醫(yī)院泌尿外科;
【基金】：廣西衛(wèi)生廳科研基金項(xiàng)目(編號:Z2010249)
【分類號】：R737.14

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張遵俊;王世先;郭昭建;范先明;;二次電切治療多發(fā)Ta期膀胱尿路上皮癌臨床分析[J];中國醫(yī)藥導(dǎo)刊;2013年11期

2 遲慶龍;王艷波;王春喜;;水飛薊賓對人膀胱癌細(xì)胞系T24和5637的增殖抑制及凋亡誘導(dǎo)作用[J];吉林大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2014年02期

3 全翔鳳;姚莉;唐冬媛;伍琳凌;潘柳霖;吳秋蘭;;膀胱癌術(shù)后早期膀胱灌注化療的護(hù)理[J];當(dāng)代護(hù)士(中旬刊);2014年05期

4 容祖益;梁建波;李偉;;初次經(jīng)尿道膀胱腫瘤電切術(shù)后腫瘤殘留的多因素分析[J];廣西醫(yī)學(xué);2014年12期

5 許天源;朱照偉;鐘山;張小華;王先進(jìn);張敏光;沈周俊;;EORTC風(fēng)險(xiǎn)量表對非肌層浸潤性膀胱癌術(shù)后即刻灌注化療預(yù)后判斷的研究[J];臨床泌尿外科雜志;2013年07期

6 許克新;;高危非肌層浸潤性膀胱癌需要再次電切嗎?[J];現(xiàn)代泌尿外科雜志;2013年06期

7 梁勝杰;鄒青松;韓邦e，

本文編號：1635875